Economic burden of asthma: implications for outcomes and cost-effectiveness analyses

References

• Beasley R, Crane J, Lai CK, Pearce N.
   Google Scholar
• •International estimates of the prevalence of asthma.
   Google Scholar
• Anonymous. Asthma Mortality and Hospitalization Among Children and
   Google Scholar
• National Heart, Lung and Blood Institute. National Asthma Education Program Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma.Human Services. (1997)
   Google Scholar
• ••Key document discussing diagnosis andtreatment of asthma.
   Google Scholar
• Barnes PJ, Jonsson B, Klim JB. The cost of asthma. Eur. Resp.j 9,636–642 (1996).
   PubMed Web of Science ®Google Scholar
• Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N. Engl. Med. 326, 862–866 (1992). Cost-of-illness study frequently cited that highlights the burden of asthma
   Google Scholar
• Weiss KB, Sullivan SD, Lyttle CS. Trends in the Cost of Illness for Asthma in the United States, 1984–1994.1 Allergy Clin. Immunol 106,493-499 (2000).Most recent asthma cost-of-illness study for USA.
   Google Scholar
• Smith DH, Malone DC, Lawson IKA, Okamoto LJ, Battista C, Saunders WB. A national estimate of the economic costs of asthma. Am. J. Rasp Grit. Care Med. 156, 787–793 (1997).
   PubMed Web of Science ®Google Scholar
• Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. I Allergy Clin. Immunol 107, 3–8 (2001).
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Weiss KB. Health economics of asthma and rhinitis. II. Assessing the value of interventions. I Allergy Clin, Immunol 107, 203–210 (2001).
   PubMed Web of Science ®Google Scholar
• Lozano P, Sullivan SD, Smith DH, Weiss KB. The economic burden of asthma in US children: estimates from the National Medical Expenditure Survey. I Allergy Clin. Immunol 104, 957–963 (1999).
   PubMed Web of Science ®Google Scholar
• Lozano P, Fishman P, VonKorff M, Hecht J. Healthcare utilization and cost among children with asthma who were enrolled in a health maintenance organization. Pediatrics 99, 757–764 (1997).
   PubMed Web of Science ®Google Scholar
• Stroupe KT, Gaskins D, Murray MD. Healthcare costs of inner-city patients with asthma. I Asthma 36,645–655 (1999).
   Google Scholar
• Stanford R, McLaughlin T, Okamoto U.The cost of asthma in the emergency department and hospital. Am. I Resp. Grit. Cam Med. 160, 211–215 (1999).
   Google Scholar
• Stempel DA, Durcannin-Robbins JF,Hedblom EC, Woolf T, Strum LL, Stempel AB. Drug utilization evaluation identifies costs associated with high use of beta-adrenergic agonists. Ann. Allergy Immunol 76,153–158 (1996).
   PubMedGoogle Scholar
• Balkrishnan R, Norwood GJ, Anderson A. Outcomes and cost benefits associated with the introduction of inhaled corticosteroid therapy in a medicaid population of asthmatic patients. Clin. Therapeutics 20, 567–580 (1998).
   Google Scholar
• Sullivan S, Elixhauser A, Buist AS, LuceBR, Eisenberg J, Weiss KB. National Asthma Education and Prevention Program Working Group Report on Cost-Effectiveness of Asthma Care. Am. j Rep. Grit. Cate Med. 154,584–595 (1996).
   Web of Science ®Google Scholar
• •Article provides recommendations with regards to conducting asthma-related cost-effectiveness analyses.
   Google Scholar
• Ungar WJ, Coyte PC, The Pharmacy Medication Monitoring Program Advisory Board. Prospective study of the patient-level cost of asthma care in children. Pediatric Pulmonology 32,101–108 (2001).
   Google Scholar
• Rutten-van Molken MP, Van Doorslaer EKA, Jansen MCC, Van Essen-Zandvliet EE, Rutten FFH. Cost-effectiveness of inhaled corticosteroids plus bronchodilator therapy versus bronchodilator monotherapy in children with asthma. PharmacoEconomics 4,257–270 (1993).
   Google Scholar
• Rutten-van Molken MP, Van Doorslaer EKA, Jansen MCC, Kerstjens AM, Rutten FFH. Costs and effects of inhaled corticosteroids and bronchodialtors in asthma and chronic obstructive pulmonary disease. Am. Resp. Grit. Care Med 151, 975–982 (1995).A well conducted cost-effectiveness analysis based on randomized trials involving inhaled corticosteroids.
   Google Scholar
• Booth PC, Capsey LJ, Langdon CG, Wells NE. Comparison of the cost effectiveness of alternative prophylactic therapies in the treatment of adult asthma. BE j Med. Econ. 8,65–72 (1995).
   Google Scholar
• Volmer T, Kielhorn A, Weber HH,Wiessmann KJ. Cost-effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthma. PharmacoEconomics 16,525–531 (1999).
   Google Scholar
• Johansson G, Price MJ, Sondhi S. Cost- effectiveness analysis of salmeterol/fluticasone propionate 50/100 mug vs fluticasone propionate 100 mug in adults and adolescents with asthma. Part 3. Results. PharmacoEconomic516, 15–21 (1999).
   Google Scholar
• Johansson G, Price MJ, Sondhi S. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/100 mug vs fluticasone propionate 100 mug in adults and adolescents with asthma. Part 3. Results. PharmacoEconomic516, 15–21 (1999).
   Google Scholar
• Pieters WR, Lundback B, Sondhi S, Price MJ,Thwaites RM. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/500 mug IS. fluticasone propionate 500 mug in patients with corticosteroid-dependent asthma. Part 5. Results. PharmacoEconomics 16,29–34 (1999).
   Google Scholar
• Lanes SF, Birmann BM, Walker AM et alCharacterisation of asthma management in the Fallon Community Health Plan from 1988 to 1991. PharmacoEconomics 10, 378–385 (1996).
   PubMedGoogle Scholar
• Szucs TD, Anderhub H, Rutishauser M.The economic burden of asthma: direct and indirect costs in Switzerland. Eur. Rep.13,281-286 (1999).
   Google Scholar
• Marion RJ, Creer TL, Reynolds RV. Direct and indirect costs associated with the management of childhood asthma. Ann. Allergy54, 31–34 (1985).
   Google Scholar
• Ungar WJ, Coyte PC. Measuringproductivity loss days in asthma patients. The Pharmacy Medication Monitoring Program and Advisory Board. Health Economics 9,37–46 (2000).
   Google Scholar
• Rutten-Van-Molken MP, Van Doorslaer EK, Denise M. Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma. PharmacoEconomics 14,671–684 (1998).
   Google Scholar
• Blanc PD, Jones M, Besson C, Katz P, Yelin E. Work disability among adults with asthma. Chest 104,1371–1377 (1993).
   PubMed Web of Science ®Google Scholar
• Blanc PD, Cisternas M, Smith S, Yelin EH. Asthma, employment status and disability among adults treated by pulmonary and allergy specialists. Chest 109,688–696 (1996).
   PubMed Web of Science ®Google Scholar
• Sculpher MJ, Buxton MJ. Episode-free day asa composite measure of effectiveness: illustrative economic evaluation of formoterol versussalbumatol in asthma therapy. PharmacoEconomic54, 345–352 (1993).
   Google Scholar
• Pieters WR, Lundback B, Johansson G,Palmqvist M, Price MJ. Cost-effectiveness analyses of salmeterol/fluticasone propionate combination product and fluticasone propionate in patients with asthma. Part 2. Study methodologies. PharmacoEconomics 16,9–14 (1999).
   Google Scholar
• Juniper EE Health-related quality of life in asthma. CI.117: Opin. Pulmonary Med. 5, 105–110 (1999).
   Google Scholar
• Spitzer WO, Suissa S, Ernst P eta]. The use of beta-agonists and the risk of death and near death from asthma. N Engl. I Med.326,501–506 (1992).
   Google Scholar
• Sullivan SD. Cost and cost-effectiveness in asthma: use of pharmacoeconomics to assess the value of asthma interventions. Immunol Allergy Clin. North Am. 16,819–839 (1996).
   Google Scholar
• Cost-effectiveness in health and medicine. Oxford University Press, New York, USA. (1997).
   Google Scholar
• Thomas P, Ross RN, Farrar JR. A retrospective assessment of cost avoidance associated with the use of nedocromil sodium metered-dose inhaler in the treatment of patients with asthma. Clin. Therapeutics 18,939–952 (1996).
   Google Scholar
• Price DB, Cargill K, Wolfe S, Darby H. Salmeterol xinafoate: an analysis of outcomes and cost-effectiveness using a primary care database. Respiratory Med. 92, 1302–1304 (1998).
   PubMedGoogle Scholar
• Andersson F, Stahl E, Barnes PJ etal. Ullman and Formoterol and Corticosteroid Establishing Therapy. International Study Group. Adding formoterol to budesonide in moderate asthma-health economic results from the FACET study. Rep. Med. 95,505–512 (2001).
   Google Scholar
• Klingman D, Bielory L, Wang Y, eta].Asthma outcome changes associated with use of the leukotriene-receptor antagonist zafirlukast. Managed Cir Interface 14,62–66 (2001).
   Google Scholar
• Price DB, Ben Joseph RII, Zhang Q.Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the UK. Respir Med. 95,83–89 (2001).
   Google Scholar
• Holzer SS, Engelhart L, Crown WH,LHerrou TA, Kennedy ST Asthma treatment costs using inhaled corticosteroids. Am. I Managed Care 3, 891–897 (1997).
   PubMedGoogle Scholar
• Adelroth PJ, Thompson S. Advantages ofhigh-dose budesonide. Lancetl (8583), 476 (1988).
   Google Scholar
• Campbell LM, Simpson RJ, Turbitt ML,Richardson PDI. A comparison of the cost-effectiveness of budesonide 400 ug/day and 800 ug/day in the management of mild-to-moderate asthma in general practice. BE Med Econ. 6,67-74 (1993).
   Google Scholar
• Connett GJ, Lenney W, McConchie SM.The cost-effectiveness of budesonide in severe asthmatics aged one to three years. Br. Med Ron. 6,127–134 (1993).
   Google Scholar
• Booth PC, Capsey LJ, Langdon CG, Wells NE. Comparison of the cost effectiveness of alternative prophylactic therapies in the treatment of adult asthma. Br. Med Econ. 8,65–72 (1995).
   Google Scholar
• Steinmetz KO, Volmer T, Trautmann M, Kielhorn A. Cost effectiveness of fluticasone and budesonide in patients with moderate asthma. Gun. Drug- Invest. 16, 117–123 (1998).
   PubMed Web of Science ®Google Scholar
• Barnes NC, Thwaites RM, Price MJ. The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children. Resp. Med 93,402–407 (1999).
   Google Scholar
• Stempel DA, Stanford RII, Thwaites R, Price MJ. Cost-efficacy comparison of inhaled fluticasone propionate and budesonide in the treatment of asthma. Gun. Therapeutics 22,1562–1574 (2000).
   Google Scholar
• Andersson F, Kjellman M, Forsberg G,Moller G, Arheden L. Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice. Ann. Allergy Asthma Immunol 86, 537–544 (2001).
   Google Scholar
• Perera BJ. Efficacy and cost effectiveness of inhaled steroids in asthma in a developing country. Arch. Dis. Childhooc172, 312–315 (1995).
   Google Scholar
• Perera BJ. Efficacy and cost effectiveness of inhaled steroids in asthma in a developing country: an epilogue. Arch. Dis. Childhood 73,482 (1995).
   PubMedGoogle Scholar
• Venables TL, McConchie S, Fellows RMA. A comparison of the cost-effectiveness of budesonide and fluticasone dry-powder devices in the mangement of asthma. Br. j Med. Econ. 10,315–323 (1996).
   Google Scholar
• Price DB, Appleby JL. Fluticasone propionate: an audit of outcomes and cost-effectiveness in primary care. Resp. Med 92, 351–353 (1998).
   PubMedGoogle Scholar
• Lundback B, Pieters WR, Johansson G, Palmqvist M, Price MJ. Cost-effectiveness analyses of salmeterol/ fluticasone propionate combination product and fluticasone propionate in patients with asthma. Part 1. Introduction and overview. PharmacoEconomics 16,1–8 (1999).
   Google Scholar
• Pieters VVR, Lundback B, Johansson G, Palmqvist M, Price MJ. Cost-effectiveness analyses of salmeterol/fluticasone propionate combination product and fluticasone propionate in patients with asthma. Part 2. Study methodologies. PhatmacoEconomics 16,9–14 (1999).
   Google Scholar
• Palmqvist M, Price MJ, Sondhi S. Cost- effectiveness analysis of salmeterol/ fluticasone propionate 50/250 mug vs. fluticasone propionate 250 mug in adults and adolescents with asthma. Part 4. Results. PharmacoEconomics 16,23–28 (1999).
   Google Scholar
• Booth PC, Wells NE, Morrison AK.Comparison of the cost effectiveness of alternative prophylactic therapies in childhood asthma. PharmacoEconomics 10, 262–268 (1996).
   Google Scholar
• Stempdel DA. Pharmacoeconomic impact of inhaled corticosteroids. Am. j Managed Cate 6(Suppl.), S382—S387 (2000).
   Google Scholar
• Stempe, DA, Mauskopf J, McLaughlin T,Yazdani C, Stanford RII. Comparison ofasthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Resp. Med. 95,227–234 (2001).
   Google Scholar